Market Gems:Stocks w/Strong Earnings and High Tech. Rank Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jerry Olson who wrote (74830)	12/9/1999 2:51:00 PM
From: kha vu	Read Replies (1) of 120523

CLPA: this is a very positive news for CLPA biz.yahoo.com <<<...Ninety-two of 96 enrolled patients were evaluable in this randomized double blind, placebo-controlled, multi-center trial. Of the 92 evaluable patients, 47 received placebo and 45 received Aptosyn. Results from the 92 evaluable patients showed that the rise in average PSA levels in the Aptosyn-treated group was significantly lower than that seen in the placebo-treated group. The company also performed a subgroup analysis in which patients were prospectively classified as high-, intermediate- and low-risk for developing metastatic disease. The one-year treatment data showed statistically significant differences in the rise in average PSA levels between Aptosyn and placebo patients in the high-risk group, and a strong trend toward significance in the intermediate risk group. The safety profile of Aptosyn was similar to those observed in previous clinical trials, with two patients discontinuing therapy due to indigestion. >>>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next